BR9714082A - Compound, use thereof, pharmaceutical composition, and, processes for treatment or prophylaxis of inflammatory diseases, and for the preparation of a compound. - Google Patents
Compound, use thereof, pharmaceutical composition, and, processes for treatment or prophylaxis of inflammatory diseases, and for the preparation of a compound.Info
- Publication number
- BR9714082A BR9714082A BR9714082-1A BR9714082A BR9714082A BR 9714082 A BR9714082 A BR 9714082A BR 9714082 A BR9714082 A BR 9714082A BR 9714082 A BR9714082 A BR 9714082A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- processes
- treatment
- inflammatory diseases
- prophylaxis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
"COMPOSTO, USO DO MESMO, COMPOSIçãO FARMACêUTICA, E, PROCESSOS PARA TRATAMENTO OU PROFILAXIA DE DOENçAS INFLAMATóRIAS, E PARA A PREPARAçãO DE UM COMPOSTO". São providos, de acordo com a invenção, novos compostos de fórmula(I): em que R^ 1^, R^ 2^ e R^ 3^ são descritos na especificação, processos para prepará-los, formulações contendo-os e seu uso em terapia para o tratamento de doenças inflamatórias."COMPOUND, USE OF THE SAME, PHARMACEUTICAL COMPOSITION, AND, PROCESSES FOR THE TREATMENT OR PROPHYLAXIS OF INFLAMMATORY DISEASES, AND FOR THE PREPARATION OF A COMPOUND". According to the invention, new compounds of formula (I) are provided: in which R ^ 1 ^, R ^ 2 ^ and R ^ 3 ^ are described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9626846.1A GB9626846D0 (en) | 1996-12-24 | 1996-12-24 | Chemical compounds |
GBGB9626845.3A GB9626845D0 (en) | 1996-12-24 | 1996-12-24 | Chemical compounds |
GBGB9626852.9A GB9626852D0 (en) | 1996-12-24 | 1996-12-24 | Chemical compounds |
GBGB9720536.3A GB9720536D0 (en) | 1997-09-27 | 1997-09-27 | Chemical compounds |
GBGB9722730.0A GB9722730D0 (en) | 1997-10-29 | 1997-10-29 | Chemical compounds |
PCT/EP1997/007197 WO1998028319A1 (en) | 1996-12-24 | 1997-12-22 | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9714082A true BR9714082A (en) | 2000-05-09 |
Family
ID=27517393
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9714082-1A BR9714082A (en) | 1996-12-24 | 1997-12-22 | Compound, use thereof, pharmaceutical composition, and, processes for treatment or prophylaxis of inflammatory diseases, and for the preparation of a compound. |
Country Status (36)
Country | Link |
---|---|
US (2) | US6426337B1 (en) |
EP (1) | EP0948509B1 (en) |
JP (1) | JP4156035B2 (en) |
KR (1) | KR20000069682A (en) |
CN (1) | CN1246124A (en) |
AP (1) | AP1105A (en) |
AR (1) | AR011044A1 (en) |
AT (1) | ATE226212T1 (en) |
AU (1) | AU733684B2 (en) |
BG (1) | BG63310B1 (en) |
BR (1) | BR9714082A (en) |
CA (1) | CA2275271A1 (en) |
CO (1) | CO4940488A1 (en) |
CZ (1) | CZ230999A3 (en) |
DE (1) | DE69716468T2 (en) |
DK (1) | DK0948509T3 (en) |
EA (1) | EA001714B1 (en) |
EE (1) | EE04019B1 (en) |
ES (1) | ES2186015T3 (en) |
GE (1) | GEP20022656B (en) |
HU (1) | HUP0000673A3 (en) |
ID (1) | ID22271A (en) |
IL (1) | IL130547A0 (en) |
IS (1) | IS5089A (en) |
NO (1) | NO312840B1 (en) |
NZ (1) | NZ336332A (en) |
OA (1) | OA11071A (en) |
PE (1) | PE27499A1 (en) |
PL (1) | PL334218A1 (en) |
PT (1) | PT948509E (en) |
SI (1) | SI0948509T1 (en) |
SK (1) | SK86599A3 (en) |
TR (1) | TR199901905T2 (en) |
TW (1) | TW528755B (en) |
WO (1) | WO1998028319A1 (en) |
YU (1) | YU29099A (en) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
YU44900A (en) | 1998-01-31 | 2003-01-31 | Glaxo Group Limited | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives |
CO4990969A1 (en) * | 1998-02-14 | 2000-12-26 | Glaxo Group Ltd | DERIVATIVES OF 2- (PURIN-9-IL) -TETRAHYDROFURAN-3,4-DIOL |
GB9813554D0 (en) * | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
GB9813565D0 (en) * | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
KR20010071591A (en) * | 1998-06-23 | 2001-07-28 | 그레이엄 브레레톤, 레슬리 에드워즈 | 2-(Purin-9-yl)-tetrahydrofuran-3,4-diol derivatives |
GB9813540D0 (en) * | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
GB9930082D0 (en) * | 1999-12-20 | 2000-02-09 | Glaxo Group Ltd | Medicaments |
US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
GB0022695D0 (en) | 2000-09-15 | 2000-11-01 | Pfizer Ltd | Purine Derivatives |
GB0104555D0 (en) * | 2001-02-23 | 2001-04-11 | Glaxo Group Ltd | New Therapeutic method |
WO2002072067A2 (en) * | 2001-03-12 | 2002-09-19 | Glaxo Group Limited | Pharmaceutical aerosol formulation |
JP2002338593A (en) * | 2001-05-22 | 2002-11-27 | Ajinomoto Co Inc | Method of producing beta-d-ribofuranose derivative or optical isomer thereof |
PE20030008A1 (en) * | 2001-06-19 | 2003-01-22 | Bristol Myers Squibb Co | DUAL INHIBITORS OF PDE 7 AND PDE 4 |
TW200519106A (en) | 2003-05-02 | 2005-06-16 | Novartis Ag | Organic compounds |
GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
TWI346109B (en) | 2004-04-30 | 2011-08-01 | Otsuka Pharma Co Ltd | 4-amino-5-cyanopyrimidine derivatives |
LT2612862T (en) | 2004-05-13 | 2017-01-25 | Icos Corporation | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
AR049384A1 (en) | 2004-05-24 | 2006-07-26 | Glaxo Group Ltd | PURINA DERIVATIVES |
KR101267202B1 (en) | 2004-05-26 | 2013-05-24 | 이노텍 파마슈티컬스 코포레이션 | Purine derivatives as adenosine a1 receptor agonists and methods of use thereof |
EP1802316B1 (en) * | 2004-09-20 | 2011-11-02 | Inotek Pharmaceuticals Corporation | Purine derivatives and methods of use thereof |
GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
GB0500785D0 (en) * | 2005-01-14 | 2005-02-23 | Novartis Ag | Organic compounds |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
CA2625664C (en) | 2005-10-21 | 2016-01-05 | Novartis Ag | Human antibodies against il13 and therapeutic uses |
GB0523845D0 (en) * | 2005-11-23 | 2006-01-04 | Glaxo Group Ltd | Novel salts |
WO2007064795A2 (en) * | 2005-11-30 | 2007-06-07 | Inotek Pharmaceuticals Corporation | Purine derivatives and methods of use thereof |
GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
EP1889846A1 (en) * | 2006-07-13 | 2008-02-20 | Novartis AG | Purine derivatives as A2a agonists |
WO2008037477A1 (en) | 2006-09-29 | 2008-04-03 | Novartis Ag | Pyrazolopyrimidines as p13k lipid kinase inhibitors |
AU2007315234A1 (en) | 2006-10-30 | 2008-05-08 | Novartis Ag | Heterocyclic compounds as antiinflammatory agents |
MX2010007604A (en) | 2008-01-11 | 2010-08-02 | Novartis Ag | Pyrimidines as kinase inhibitors. |
US9492449B2 (en) | 2008-11-13 | 2016-11-15 | Gilead Calistoga Llc | Therapies for hematologic malignancies |
KR20170060179A (en) | 2008-11-13 | 2017-05-31 | 길리아드 칼리스토가 엘엘씨 | Therapies for hematologic malignancies |
WO2010088335A1 (en) | 2009-01-29 | 2010-08-05 | Novartis Ag | Substituted benzimidazoles for the treatment of astrocytomas |
SG175259A1 (en) * | 2009-04-20 | 2011-11-28 | Gilead Calistoga Llc | Methods of treatment for solid tumors |
KR20120049281A (en) | 2009-07-21 | 2012-05-16 | 길리아드 칼리스토가 엘엘씨 | Treatment of liver disorders with pi3k inhibitors |
US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
BR112012003262A8 (en) | 2009-08-12 | 2016-05-17 | Novartis Ag | Heterocyclic Hydrazone Compounds and Their Uses to Treat Cancer and Inflammation |
IN2012DN01961A (en) | 2009-08-17 | 2015-08-21 | Intellikine Llc | |
CA2771432A1 (en) | 2009-08-20 | 2011-02-24 | Novartis Ag | Heterocyclic oxime compounds |
US20120238520A1 (en) * | 2009-12-09 | 2012-09-20 | David Lipson | Novel Medical Use |
BR112012017106A2 (en) | 2010-01-11 | 2018-05-29 | Inotek Pharmaceuticals Corp | combination, kit and method of intraocular pressure reduction. |
SG184221A1 (en) | 2010-03-26 | 2012-10-30 | Inotek Pharmaceuticals Corp | Method of reducing intraocular pressure in humans using n6 -cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof |
WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
UY33597A (en) | 2010-09-09 | 2012-04-30 | Irm Llc | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF THE TRK |
AU2012205791B2 (en) * | 2011-01-10 | 2016-11-03 | Invion, Ltd. | Use of beta-adrenergic inverse agonists for smoking cessation |
WO2012107500A1 (en) | 2011-02-10 | 2012-08-16 | Novartis Ag | [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase |
EP2678016B1 (en) | 2011-02-23 | 2016-08-10 | Intellikine, LLC | Heterocyclic compounds and uses thereof |
BR112013021638A2 (en) | 2011-02-25 | 2016-08-02 | Irm Llc | "trk inhibiting compounds, their use and compositions comprising them" |
MX339302B (en) | 2011-09-15 | 2016-05-19 | Novartis Ag | 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase. |
WO2013078440A2 (en) | 2011-11-23 | 2013-05-30 | Intellikine, Llc | Enhanced treatment regimens using mtor inhibitors |
MX2014009086A (en) | 2012-01-26 | 2015-06-05 | Inotek Pharmaceuticals Corp | Anhydrous polymorphs of (2r,3s,4r,5r)-5-(6-(cyclopentylamino)-9h- purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl) } methyl nitrate and processes of preparation thereof. |
KR20140133590A (en) | 2012-03-05 | 2014-11-19 | 길리아드 칼리스토가 엘엘씨 | Polymorphic forms of (s)-2-(1-(9h-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3h)-one |
ES2894830T3 (en) | 2012-04-03 | 2022-02-16 | Novartis Ag | Combination products with tyrosine kinase inhibitors and their use |
CN104902889A (en) * | 2012-09-21 | 2015-09-09 | 罗得岛医院 | Inhibitors of beta-hydrolase for treatment of cancer |
NZ630759A (en) | 2013-03-15 | 2017-07-28 | Inotek Pharmaceuticals Corp | Ophthalmic formulations comprising an a1 agonist |
WO2014151147A1 (en) | 2013-03-15 | 2014-09-25 | Intellikine, Llc | Combination of kinase inhibitors and uses thereof |
TW201605450A (en) | 2013-12-03 | 2016-02-16 | 諾華公司 | Combination of Mdm2 inhibitor and BRAF inhibitor and their use |
EP3594215A1 (en) | 2013-12-20 | 2020-01-15 | Gilead Calistoga LLC | Intermediate products in process methods for the preparation of phosphatidylinositol 3-kinase inhibitors |
EP3083623A1 (en) | 2013-12-20 | 2016-10-26 | Gilead Calistoga LLC | Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one |
EP3154960A1 (en) | 2014-06-13 | 2017-04-19 | Gilead Sciences, Inc. | Phosphatidylinositol 3-kinase inhibitors |
WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
US10195208B2 (en) | 2014-07-31 | 2019-02-05 | Novartis Ag | Combination therapy |
WO2018049145A1 (en) | 2016-09-09 | 2018-03-15 | Calithera Biosciences, Inc. | Ectonucleotidase inhibitors and methods of use thereof |
SG11202012001YA (en) | 2018-06-21 | 2021-01-28 | Calithera Biosciences Inc | Ectonucleotidase inhibitors and methods of use thereof |
CN114008048A (en) * | 2019-06-20 | 2022-02-01 | 卡利泰拉生物科技公司 | Exonucleotidase inhibitors and methods of use thereof |
TW202140550A (en) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | Methods of treating an inflammatory or obstructive airway disease using anti-tslp antibody |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE768925A (en) | 1970-06-30 | 1971-11-03 | Takeda Chemical Industries Ltd | ADENOSINE DERIVATIVES AND METHOD OF PREPARATION |
DE2034785A1 (en) | 1970-07-14 | 1972-01-20 | Boehnnger Mannheim GmbH, 6800 Mann heim Waldhof | Adenosine 5 carboxylic acid derivatives |
CA1019727A (en) | 1971-03-18 | 1977-10-25 | Abbott Laboratories | Adenosine-5'-carboxylic acid amides |
BE789773A (en) | 1971-10-08 | 1973-04-06 | Schering Ag | ADENOSINES N6 -SUBSTITUTED AND THEIR PROCESS FOR |
US3864483A (en) | 1972-03-22 | 1975-02-04 | Abbott Lab | Adenosine-5{40 -carboxylic acid amides |
CA1082695A (en) | 1972-04-10 | 1980-07-29 | Francis E. Fischer | Process for preparing adenosine-5'-carboxamides |
US3966917A (en) | 1974-07-30 | 1976-06-29 | Abbott Laboratories | Platelet aggregation inhibitors |
DE2621470A1 (en) * | 1976-05-14 | 1977-12-01 | Pharma Waldhof Gmbh & Co | Nucleoside carboxylic acid nitriles and derivs. - prepd. from a (5')-(O)-tosylated or halogenated nucleoside and a metal cyanide or alpha:alkali acetic acid |
US4167565A (en) | 1976-11-08 | 1979-09-11 | Abbott Laboratories | Adenosine-5'-carboxamides and method of use |
AU8379182A (en) | 1981-06-04 | 1982-12-09 | Procter & Gamble Company, The | Composition of salicylates and purine derivatives |
CA1239397A (en) | 1983-08-01 | 1988-07-19 | James A. Bristol | N.sup.6-substituted adenosines |
DE3406533A1 (en) | 1984-02-23 | 1985-08-29 | Boehringer Mannheim Gmbh, 6800 Mannheim | USE OF ADENOSINE DERIVATIVES AS ANTIALLERGICA AND MEDICINAL PRODUCTS CONTAINING THEM |
US4496643A (en) | 1984-03-23 | 1985-01-29 | Eastman Kodak Company | Two-component dry electrostatic developer composition containing onium charge control agent |
JPH0655756B2 (en) | 1984-04-18 | 1994-07-27 | ネルソン・リサ−チ・アンド・デベロツプメント・カンパニ− | N-6-substituted adenosine derivatives as cardiovascular vasodilators |
US5310731A (en) | 1984-06-28 | 1994-05-10 | Whitby Research, Inc. | N-6 substituted-5'-(N-substitutedcarboxamido)adenosines as cardiac vasodilators and antihypertensive agents |
US4663313A (en) | 1984-10-26 | 1987-05-05 | Warner-Lambert Company | N6 -tricyclic adenosines for treating hypertension |
AU575438B2 (en) | 1984-10-26 | 1988-07-28 | Warner-Lambert Company | N6 - substituted deoxyribose analogues of adenosines |
US4738954A (en) | 1985-11-06 | 1988-04-19 | Warner-Lambert Company | Novel N6 -substituted-5'-oxidized adenosine analogs |
US4755594A (en) | 1986-01-31 | 1988-07-05 | Warner-Lambert Company | N6 -substituted adenosines |
US5106837A (en) | 1988-03-16 | 1992-04-21 | The Scripps Research Institute | Adenosine derivatives with therapeutic activity |
US4767747A (en) | 1986-08-28 | 1988-08-30 | Warner-Lambert Company | Method for treating congestive heart failure with N6 -acenaphthyl adenosine |
AU8274187A (en) | 1986-10-31 | 1988-05-25 | Warner-Lambert Company | Heteroaromatic derivatives of adenosine |
WO1988003147A1 (en) | 1986-10-31 | 1988-05-05 | Warner-Lambert Company | Selected n6-substituted adenosines having selective a2 binding activity |
HU198950B (en) | 1986-12-15 | 1989-12-28 | Sandoz Ag | Process for producing new furanuronic acid derivatives and pharmaceutical compositions comprising such compounds |
US4968697A (en) | 1987-02-04 | 1990-11-06 | Ciba-Geigy Corporation | 2-substituted adenosine 5'-carboxamides as antihypertensive agents |
FI880405A (en) | 1987-02-04 | 1988-08-05 | Ciba Geigy Ag | Adenosine-5'-KARBOXAMIDDERIVAT. |
US4962194A (en) | 1987-04-02 | 1990-10-09 | Warner-Lambert Company | Method of preparing 51,N6-disubstituted adenosines from inosines |
US5219840A (en) | 1987-04-06 | 1993-06-15 | Sandoz Ltd. | Antihypertensive 9-(2,N6 -disubstituted adenyl) ribofuranuronic acid derivatives |
LU87181A1 (en) | 1987-04-06 | 1988-11-17 | Sandoz Sa | NOVEL DERIVATIVES OF FURANNURONIC ACID, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS |
JPH0725785B2 (en) | 1989-01-11 | 1995-03-22 | 日本臓器製薬株式会社 | Adenosine derivative and pharmaceutical composition containing the compound as an active ingredient |
US5055569A (en) | 1989-10-19 | 1991-10-08 | G. D. Searle & Co. | N-(6)-substituted adenosine compounds |
CA2028002A1 (en) | 1989-10-19 | 1991-04-20 | Daniel P. Becker | Method of treating gastrointestinal motility disorders |
US5140015A (en) | 1990-02-20 | 1992-08-18 | Whitby Research, Inc. | 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents |
US5280015A (en) | 1990-09-05 | 1994-01-18 | The United States Of America As Represented By The Department Of Health And Human Services | 2-substituted adenosines and 2-substituted adenosine 5'-carboxamides |
ATE147074T1 (en) | 1990-09-25 | 1997-01-15 | Rhone Poulenc Rorer Int | COMPOUNDS WHICH POSSESS ANTIHYPERTENSIVE AND ANTIISCHEMIC PROPERTIES |
FR2685918B1 (en) | 1992-01-08 | 1995-06-23 | Union Pharma Scient Appl | NOVEL ADENOSINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
FR2687678B1 (en) | 1992-01-31 | 1995-03-31 | Union Pharma Scient Appl | NOVEL ADENOSINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
US5424297A (en) | 1992-04-27 | 1995-06-13 | University Of Virginia Alumni Patents Foundation | Adenosine dextran conjugates |
AU4772493A (en) | 1992-07-15 | 1994-02-14 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | Sulfo-derivatives of adenosine |
GB9301000D0 (en) | 1993-01-20 | 1993-03-10 | Glaxo Group Ltd | Chemical compounds |
EP0684953A4 (en) | 1993-02-03 | 1999-12-22 | Gensia Inc | Adenosine kinase inhibitors comprising lyxofuranosyl derivatives. |
WO1995002604A1 (en) | 1993-07-13 | 1995-01-26 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | A3 adenosine receptor agonists |
US5446046A (en) | 1993-10-28 | 1995-08-29 | University Of Florida Research Foundation | A1 adenosine receptor agonists and antagonists as diuretics |
WO1995018817A1 (en) | 1994-01-07 | 1995-07-13 | Laboratoires Upsa | Novel adenosine derivatives, preparation methods therefor, and pharmaceutical compositions containing same |
GB9414208D0 (en) | 1994-07-14 | 1994-08-31 | Glaxo Group Ltd | Compounds |
GB9414193D0 (en) | 1994-07-14 | 1994-08-31 | Glaxo Group Ltd | Compounds |
-
1997
- 1997-12-16 TW TW086118941A patent/TW528755B/en active
- 1997-12-22 IL IL13054797A patent/IL130547A0/en unknown
- 1997-12-22 AR ARP970106111A patent/AR011044A1/en not_active Application Discontinuation
- 1997-12-22 YU YU29099A patent/YU29099A/en unknown
- 1997-12-22 GE GEAP19974870A patent/GEP20022656B/en unknown
- 1997-12-22 CZ CZ992309A patent/CZ230999A3/en unknown
- 1997-12-22 KR KR1019997005729A patent/KR20000069682A/en not_active Application Discontinuation
- 1997-12-22 PT PT97953888T patent/PT948509E/en unknown
- 1997-12-22 SI SI9730455T patent/SI0948509T1/en unknown
- 1997-12-22 CA CA002275271A patent/CA2275271A1/en not_active Abandoned
- 1997-12-22 NZ NZ336332A patent/NZ336332A/en unknown
- 1997-12-22 BR BR9714082-1A patent/BR9714082A/en not_active IP Right Cessation
- 1997-12-22 US US09/331,526 patent/US6426337B1/en not_active Expired - Lifetime
- 1997-12-22 AT AT97953888T patent/ATE226212T1/en not_active IP Right Cessation
- 1997-12-22 DK DK97953888T patent/DK0948509T3/en active
- 1997-12-22 AP APAP/P/1999/001572A patent/AP1105A/en active
- 1997-12-22 HU HU0000673A patent/HUP0000673A3/en unknown
- 1997-12-22 EP EP97953888A patent/EP0948509B1/en not_active Expired - Lifetime
- 1997-12-22 ES ES97953888T patent/ES2186015T3/en not_active Expired - Lifetime
- 1997-12-22 DE DE69716468T patent/DE69716468T2/en not_active Expired - Lifetime
- 1997-12-22 SK SK865-99A patent/SK86599A3/en unknown
- 1997-12-22 WO PCT/EP1997/007197 patent/WO1998028319A1/en not_active Application Discontinuation
- 1997-12-22 JP JP52838098A patent/JP4156035B2/en not_active Expired - Fee Related
- 1997-12-22 AU AU57622/98A patent/AU733684B2/en not_active Ceased
- 1997-12-22 ID IDW990575A patent/ID22271A/en unknown
- 1997-12-22 EA EA199900494A patent/EA001714B1/en not_active IP Right Cessation
- 1997-12-22 PL PL97334218A patent/PL334218A1/en unknown
- 1997-12-22 CN CN97181854A patent/CN1246124A/en active Pending
- 1997-12-22 TR TR1999/01905T patent/TR199901905T2/en unknown
- 1997-12-22 EE EEP199900312A patent/EE04019B1/en not_active IP Right Cessation
- 1997-12-23 CO CO97074732A patent/CO4940488A1/en unknown
- 1997-12-23 PE PE1997001160A patent/PE27499A1/en not_active Application Discontinuation
-
1999
- 1999-06-22 BG BG103518A patent/BG63310B1/en unknown
- 1999-06-22 IS IS5089A patent/IS5089A/en unknown
- 1999-06-22 OA OA9900139A patent/OA11071A/en unknown
- 1999-06-23 NO NO19993114A patent/NO312840B1/en unknown
-
2001
- 2001-12-19 US US10/025,678 patent/US6528494B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9714082A (en) | Compound, use thereof, pharmaceutical composition, and, processes for treatment or prophylaxis of inflammatory diseases, and for the preparation of a compound. | |
BR9911482A (en) | Compound, pharmaceutical composition, use of the compound, and, processes for the treatment or prophylaxis of inflammatory diseases, and for the preparation of a compound | |
BR9911488A (en) | Compound, use of it, pharmaceutical composition, and processes for the treatment or prophylaxis of inflammatory diseases, and for the preparation of a compound | |
BR9907270A (en) | Compound, pharmaceutical composition, use of a compound, and, processes for the treatment or prophylaxis of inflammatory diseases, for example, asthma or copd, and for the preparation of a compound | |
BR9907886A (en) | Compound, use of it, pharmaceutical composition, and, treatment process or prophylaxis of inflammatory diseases, for example asthma or copd. | |
BR9916282A (en) | Compound, use of a compound and method of treatment | |
BR0114321A (en) | Compound, pharmaceutical composition, use of a compound, method of treating or prophylaxis of inflammatory diseases, and process for preparing a compound | |
BR9806870A (en) | Compound, process for the prophylaxis or treatment of a clinical condition in a mammal, pharmaceutical formulation, and use of a compound and process to prepare it. | |
BR9507917A (en) | Reagent to prepare a radiopharmaceutical agent image forming agent process to prepare the same kit to prepare a pharmaceutical preparation use of the reagent composition radiotherapeutic agent and radiopharmaceutical agent | |
YU56995A (en) | ONLY DERIVED INDOLA | |
BR0113176A (en) | Bicyclo-pyrazole compounds, pharmaceutical compositions comprising the compounds, use of the compounds in the manufacture of medicaments, processes for the preparation of the compounds, combinatorial chemical collection and methods for the treatment of mammals including humans using the compounds. | |
BR9811022A (en) | Compound, pharmaceutical composition, and process for preparing a compound | |
BR9813373A (en) | Compound, process for preparing it, pharmaceutical composition, process for preparing it, use of a compound, and, processes for effecting immunosuppression and for treating or reducing the risk of reversibly obstructive airway disease in a patient | |
BR0108678A (en) | New compounds | |
BR9813378A (en) | Compound, process for preparing the same, and use of it, pharmaceutical composition, and process for preparing the same, and process for effecting immunosuppression | |
BG101118A (en) | Therapeutical compounds | |
BR9810592A (en) | Compound, processes for preparing a compound, for treating or preventing diseases of the endocrine system and for the manufacture of a drug, pharmaceutical composition, and, use of a compound | |
BR9808953A (en) | Compound, process to treat a cyclooxygenase-2 mediated disorder in a patient, and pharmaceutical composition | |
BRPI0215312B8 (en) | compound, use of a compound, pharmaceutical composition, and process for preparing a compound | |
BRPI0113042B8 (en) | compound of the formula or a physiologically acceptable solvate thereof, use thereof, pharmaceutical composition, pharmaceutical formulation, method of treating a human or animal subject with an inflammatory and/or allergic condition, and, process for preparing a compound or a solvate thereof | |
WO1998056761A3 (en) | Benzimidazole derivatives | |
BR0108600A (en) | Compound, process for preparing it, pharmaceutical composition, process for preparing it, use of a compound, and methods for treating a chemokine-mediated disease and for treating an inflammatory disease | |
BR0309498A (en) | Compounds, pharmaceutical compositions, method for the treatment or prophylaxis of ras-related diseases, and use of compounds | |
BR9812492A (en) | Compound, use of it, pharmaceutical formulation, and processes for the treatment of cardiovascular disease, for the treatment of vasoconstriction, and for the preparation of compounds | |
AR019496A1 (en) | AZALIDAS OF 13 MEMBERS, PHARMACEUTICAL COMPOSITIONS, USE IN THE PREPARATION OF MEDICINES AND PREPARATION OF THE SAME |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A, 8A E 9A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1894 DE 24/04/2007. |